[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB201711855D0 - Cancer therapy - Google Patents

Cancer therapy

Info

Publication number
GB201711855D0
GB201711855D0 GBGB1711855.5A GB201711855A GB201711855D0 GB 201711855 D0 GB201711855 D0 GB 201711855D0 GB 201711855 A GB201711855 A GB 201711855A GB 201711855 D0 GB201711855 D0 GB 201711855D0
Authority
GB
United Kingdom
Prior art keywords
cancer therapy
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1711855.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Van Andel Research Institute
Original Assignee
National University of Singapore
Van Andel Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore, Van Andel Research Institute filed Critical National University of Singapore
Priority to GBGB1711855.5A priority Critical patent/GB201711855D0/en
Publication of GB201711855D0 publication Critical patent/GB201711855D0/en
Priority to PCT/SG2018/050362 priority patent/WO2019022662A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1711855.5A 2017-07-24 2017-07-24 Cancer therapy Ceased GB201711855D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1711855.5A GB201711855D0 (en) 2017-07-24 2017-07-24 Cancer therapy
PCT/SG2018/050362 WO2019022662A1 (en) 2017-07-24 2018-07-24 The prevention of side-effects in cancer and fibrosis therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1711855.5A GB201711855D0 (en) 2017-07-24 2017-07-24 Cancer therapy

Publications (1)

Publication Number Publication Date
GB201711855D0 true GB201711855D0 (en) 2017-09-06

Family

ID=59771766

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1711855.5A Ceased GB201711855D0 (en) 2017-07-24 2017-07-24 Cancer therapy

Country Status (2)

Country Link
GB (1) GB201711855D0 (en)
WO (1) WO2019022662A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114025764A (en) * 2019-05-22 2022-02-08 新加坡科技研究局 Pharmaceutical combination

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359444B2 (en) * 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor

Also Published As

Publication number Publication date
WO2019022662A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination cancer therapy
IL254705B (en) Combination therapy for cancer
HUE064857T2 (en) Combination therapy against cancer
GB201707153D0 (en) Therapy
HK1258319A1 (en) Cancer therapy
ZA202005847B (en) Cancer therapy
PT3576740T (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
IL268463A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
IL274626A (en) Cancer treatment
GB201519734D0 (en) Cancer therapy
GB201704909D0 (en) Cancer therapy
GB201711855D0 (en) Cancer therapy
HK1254687A1 (en) Combination therapy for cancer
HRP20210383T8 (en) Combination therapy for cancer
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy
GB201706046D0 (en) Cancer therapy
GB201700772D0 (en) Cancer therapy
GB201806463D0 (en) Cancer therapy
GB201713852D0 (en) Cancer treatment
GB201720533D0 (en) Cancer treatments
GB201601248D0 (en) Cancer therapy
GB201707183D0 (en) Macrophage-based therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)